Neurofibromatosis type 1: Its association with the Ras/MAPK pathway syndromes

Journal of Pediatric Neurology

Volumn 7, Issue 2, 2009, Pages 105-115

  Bennett, Emma ^a   Thomas, Nick ^a   Upadhyaya, Meena ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Genotype phenotype; MPNST; Neurofibromas; Neurofibromatosis type 1; RAS MAPK pathway; SPRED1

Indexed keywords

MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROTEIN SPRED; RAS PROTEIN; SPROUTY PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ATTENTION DEFICIT DISORDER; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG MECHANISM; GENE DELETION; GENE INACTIVATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LEARNING DISORDER; MUTATIONAL ANALYSIS; NEUROCARDIOFACIAL CUTANEOUS SYNDROME; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; PERIPHERAL NERVE TUMOR; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKELETON MALFORMATION; TUMOR GROWTH;

EID: 65449184541     PISSN: 13042580     EISSN: 18759041     Source Type: Journal    
DOI: 10.3233/JPN-2009-0276     Document Type: Review

References (48)

1. S.M. Huson, The neurofibromatosis: Classification, clinical features and genetic counselling, in: Neurofibromatoses, D. Kaufmann, ed., Karger: Basel, 2008, pp. 1-20.
2. M. Upadhyaya, S.M. Huson, M. Davies et al., An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): Evidence of a clinically significant NF1 genotype-phenotype correlation, Am J Hum Genet 80 (2007), 140-151.
3. M. Zöller, B. Rembeck, H.O. Akesson and L. Angervall, Life expectancy, mortality and prognostic factors in neurofibromatosis type 1, A twelve-year follow-up of an epidemiological study in Göteborg, Sweden, Acta Derm Venereol 75 (1995), 136-140.
4. G. Spurlock, S. Griffiths, J. Uff and M. Upadhyaya, Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types, Fam Cancer 6 (2007), 463-471.
5. M. Upadhyaya, L. Kluwe, G. Spurlock et al., Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs), Hum Mutat 29 (2008), 74-82.
6. D.G.R. Evans, M.E. Baser, J. McGaughran, S. Sharif, E. Howard and A. Moran, Malignant peripheral nerve sheath tumours in neurofibromatosis 1, J Med Genet 39 (2002), 311-314.
7. R.E. Ferner, S.M. Huson, N. Thomas et al., Guidelines for the diagnosis and management of individuals with neurofibromatosis 1, J Med Genet 44 (2007), 81-88.
8. O. Maertens, S. De Schepper, J. Vandesompele et al., Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1, Am J Hum Genet 81 (2007), 243-251.
9. M. Upadhyaya and D.N. Cooper, The mutational spectrum in neurofibromatosis 1 and its underlying mechanisms, in: Neurofibromatosis Type 1 from Genotype to Phenotype, M. Upadhyaya and D.N.Cooper, eds, Oxford: BIOS Scientific Publishers, 1998, pp. 65-82.
10. K. Cichowski and T. Jacks, NF1 tumor suppressor gene function: Narrowing the GAP, Cell 104 (2001), 593-604.
11. A.I. McClatchey, Neurofibromatosis. Annu Rev Pathol 2 (2007), 191-216.
12. D. Arun and D. Gutmann, Recent advances in neurofibromatosis type 1, Curr Opin Neurol 17 (2004), 101-105.
13. M.P. Horan, D.N. Cooper and M. Upadhyaya, Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours, Hum Genet 107 (2000), 33-39.
14. L. Fishbein, B. Eady, N. Sanek, D. Muir and M.R. Wallace, Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells, Cancer Genet Cytogenet 157 (2005), 181-186.
15. F. Hannan, I. Ho, J.J. Tong, Y. Zhu, P. Nurnberg and Y. Zhong, Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras, Hum Mol Genet 15 (2006), 1087-1098.
16. I. The, G.E. Hannigan, G.S. Cowley et al., Rescue of a Drosophila NF1 mutant phenotype by protein kinase A, Science 276 (1997), 791-794.
17. M.M. Feldkamp, L. Angelov and A. Guha, Neurofibromatosis type 1 peripheral nerve tumors: Aberrant activation of the Ras pathway, Surg Neurol 51 (1999), 211-218.
18. E. Serra, T. Rosenbaum, U. Winner et al., Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two Schwann cells subpopulations, Hum Mol Genet 9 (2000), 3055-3064.
19. H. Zheng, L. Chang, N. Patel et al., Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation, Cancer Cell 13 (2008), 117-128.
20. N.M. Joseph, J.T. Mosher, J. Buchstaller et al., The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells, Cancer Cell 13 (2008), 129-140.
21. M. Kar, S.V. Deo, N.K. Shukla et al., Malignant peripheral nerve sheath tumors (MPNST)-clinicopathological study and treatment outcome of twenty-four cases, World J Surg Oncol 4 (2006), 55.
22. Y. Zhu, P. Ghosh, P. Charnay, D.K. Burns and L.F. Parada, Neurofibromas in NF1: Schwann cell origin and role of tumor environment, Science 296 (2002), 920-922.
23. L.Q. Le and L.F. Parada, Tumor microenvironment and neurofibromatosis type 1: Connecting the GAPs, Oncogene 26 (2007), 4609-4616.
24. M.T. Acosta, G.A. Gioia and A.J. Silva, Neurofibromatosis type 1: New insights into neurocognitive issues, Curr Neurol Neurosci Rep 6 (2006), 136-143.
25. B. Grisart, K. Rack, S. Vidrequin et al., NF1 microduplication first clinical report: Association with mild mental retardation, early onset of baldness and dental enamal hypoplasia? Eur J Hum Genet 16 (2008), 305-311.
26. M.J. Descheemaeker, K. Roelandts, T. De Raedt, H. Brems, J.P. Fryns and E. Legius, Intelligence in individuals with a neurofibromatosis type 1 microdeletion, Am J Med Genet 131 (2004), 325-326.
27. H.F. Guo, J. Tong, F. Hannan, L. Luo and Y. Zhong, A neurofibromatosis-1-regulated pathway is required for learning in Drosophila, Nature 403 (2000), 895-898.
28. Y.P. Hsueh, Neurofibromin signaling and synapses, J Biomed Sci 14 (2007), 461-466.
29. W. Li, Y. Cui, S.A. Kushner et al., The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1, Curr Biol 15 (2005), 1961-1967.
30. L. Kluwe, M. Tatagiba, C. Funsterer and V.F. Mautner, NF1 mutations and clinical spectrum in patients with spinal neurofibromas, J Med Genet 40 (2003), 368-371.
31. L. Messiaen, T. Callens, J.B. Williams et al., Genotype-phenotype correlations in spinal NF, Am J Hum Genet (2007), A985.
32. S. Schubbert, K. Shannon and G. Bollag, Hyperactive Ras in developmental disorders and cancer, Nat Rev Cancer 7 (2007), 295-308.
33. O.N. Gottfried, D.H. Viskochil, D.W. Fults and W.T. Couldwell, Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications, Neurosurgery 58 (2006), 1-16.
34. M. Bentires-Alj, M.I. Kontaridis and B.G. Neel, Stops along the RAS pathway in human genetic disease, Nat Med 12 (2006), 283-285.
35. C. Nava, N. Hanna, C. Michot et al., Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome, J Med Genet 44 (2007), 763-771.
36. A.M. Nyström, S. Ekvall, E. Berglund et al., Noonan and cardio-facio-cutaneous syndromes: Two clinically and genetically overlapping disorders, J Med Genet 45 (2008), 500-506.
37. E. Denayer, T. de Ravel and E. Legius, Clinical and molecular aspects of Ras-related disorders, J Med Genet 45 (2008), 695-703.
38. H. Brems, M. Chmara, M. Sahbatou et al., Germline lossof- function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype, Nat Genet 39 (2007), 1120-1126.
39. K. Bundschu, U. Walter and K. Schuh, Getting a first clue about SPRED functions, Bioessays 29 (2007), 897-907.
40. T. Yoshida, T. Hisamoto, J. Akiba et al., Spreds, inhibitors of the Ras/ ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors, Oncogene 25 (2006), 6056-6066.
41. P. Bandipalliam, Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations, Fam Cancer 4 (2005), 323-333.
42. H. Alotaibi, M.D. Ricciardone and M. Ozturk, Homozygosity at variant MLH1 can lead to secondary mutation in NF1 and early onset leukemia, Mutat Res 637 (2008), 209-214.
43. K. Wimmer and J. Etzler, Constitutional mismatch repairdeficiency syndrome: Have so far seen only the tip of an iceberg? Hum Genet 124 (2008), 105-122.
44. D.B. Solit, L.A. Garraway, C.A. Pratilas et al., BRAFmutation predicts sensitivity to MEK inhibition, Nature 439 (2006), 358-362.
45. L.C. Krab, A. de Goede-Bolder, F.K. Aarsen et al., Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial, JAMA 300 (2008), 287-294.
46. M. Kolanczyk, J. Kuhnisch, N. Kossler et al., Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin, BMC Med 6 (2008), 21.
47. C.M. Johannessen, B.W. Johnson, S.M. Williams et al., TORC1 is essential for NF1-associated malignancies, Curr Biol 18 (2008), 56-62.
48. K.A. Rauen, HRAS and the Costello syndrome, Clin Genet 71 (2007), 101-108.